NeuroVive Pharmaceutical has reported positive topline results from a Phase I trial evaluating KL1333 for the treatment of orphan genetic mitochondrial diseases.

South Korean pharmaceutical company Yungjin Pharm was also involved in the dose block-randomised, double-blind, placebo-controlled, single-dose, dose-escalation study.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

During the trial, 25mg, 50mg, 100mg, 400mg, 600mg and 800mg doses of KL1333 were administered to 60 healthy volunteers to evaluate the drug’s pharmacokinetics, safety and tolerability.

Findings from the trial have showed that KL1333 has a highly favourable and very clear dose-proportional pharmacokinetic (PK) profile.

The trial did not report any serious adverse events (SAEs), and reported that only mild gastrointestinal adverse events (AEs) were at higher doses.

“With the convincing safety profile of KL1333 and favourable PK data, we will confidently bring this promising programme forward in development with the highest priority.”

NeuroVive Pharmaceutical CEO Erik Kinnman said: “With the convincing safety profile of KL1333 and favourable PK data, we will confidently bring this promising programme forward in development with the highest priority.

“The next important step is the clinical Phase I multiple ascending dose (MAD) study, which will take us further towards the goal of offering a novel treatment to patients with severe genetic mitochondrial disease with few or no treatment options.”

The MAD trial will include two parts, including a dose escalation phase in healthy volunteers, and a multiple dosing of patients with genetic mitochondrial disease.

It will try to further investigate safety and pharmacokinetics of KL1333 before beginning a Phase II efficacy clinical trial.

The trial is expected to be carried out at different sites in the UK in the second half of this year and plans to publish results by the first half of next year.

For the MAD trial, NeuroVive will partner with a major global contract research organisation (CRO) to rapidly progress the planning and preparation of the MAD study.